Icon

LARIAM (nda019591)- (250MG)

MEFLOQUINE HYDROCHLORIDE ROCHE
250MG
Yes No
2004-Oct-01 Expired
None None
None No
Lariam is indicated for the treatment of mild to moderate acute malaria caused by mefloquine susceptible strains of P. falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax. There are insufficient clinical data to document the effect of mefloquine in malaria caused by P. ovale or P. malariae. Lariam is indicated for the prophylaxis of P. falciparum and P. vivax malaria infections, including prophylaxis of chloroquine-resistant strains of P. falciparum.
2 0 2
Total Other Developers None
Drugs with Suitability No
250MG ** ** - - 1
NDA Sales Available Total Generic Sales Available
No 2
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ***** ****-**** ******** ***. *********** **** ****** ****, ********, **** (**) *****, ****** ****** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.